John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations

   John Northcott Joins Lexicon as Vice President of Marketing, Commercial
                           Strategy and Operations

PR Newswire

THE WOODLANDS, Texas, June 18, 2013

THE WOODLANDS, Texas, June 18, 2013 /PRNewswire/ --Lexicon Pharmaceuticals,
Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering
breakthrough treatments for human disease, announced today that John Northcott
has joined the company as its vice president of marketing, commercial
strategy, and operations. Mr. Northcott brings extensive commercial experience
to Lexicon, including both pre-launch planning and on-market commercialization
across a variety of therapeutic areas.

Mr. Northcott has held commercial roles in both U.S. and Global marketing for
Avastin® with Genentech and the Roche Group, having most recently served as
International Business Leader for Avastin, leading global product strategy
initiatives in oncology. In addition, Mr. Northcotthas experiencein a
variety of therapeutic areas from previous commercial positions at other
pharmaceutical companies including Merck and Pfizer.

In this new position, Mr. Northcott will develop the commercial functions for
Lexicon and lead the commercialization of Lexicon's products, with initial
focus on telotristat etiprate for carcinoid syndrome. The creation of the
position reflects the progress of the company's drug development pipeline and
is part of its plan to commercialize one or more drugs in specialty
indications. Lexicon is progressing with enrollment in the pivotal Phase 3
trial of telotristat etiprate in carcinoid syndrome, which has Orphan and Fast
Track status from the FDA as well as Orphan status in Europe. In addition,
Lexicon is proceeding with preparations for the initiation of Phase 3 clinical
trials of LX4211 in type 2 diabetes and is completing the Phase 2 program of
LX1033 in irritable bowel syndrome.

"John is a talented commercial leader with extensive, highly-relevant
experience," said Dr. Arthur T. Sands, president and chief executive officer
of Lexicon. "He will be instrumental in formulating and executing the
strategic and operational plans essential to bring Lexicon's innovative
products to patients."

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough
treatments for human disease. Lexicon currently has multiple programs in
clinical development for diabetes, irritable bowel syndrome, carcinoid
syndrome and other indications, all of which were discovered by Lexicon's
research team. Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has focused drug
discovery efforts on these biologically-validated targets to create its
extensive pipeline of clinical and preclinical programs. For additional
information about Lexicon and its programs, please visit

Safe Harbor Statement
This press release contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual property, as
well as other matters that are not historical facts or information. All
forward-looking statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to successfully
conduct preclinical and clinical development of its potential drug candidates,
advance additional candidates into preclinical and clinical development,
obtain necessary regulatory approvals, achieve its operational objectives,
obtain patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial value of its
drug candidates, that may cause Lexicon's actual results to be materially
different from any future results expressed or implied by such forward-looking
statements. Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year ended
December 31, 2012, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such forward-looking
statements, whether as a result of new information, future events or

SOURCE Lexicon Pharmaceuticals, Inc.

Contact: Alex Abuin, Ph.D., Vice President, Communications and Alliance
Management, +1-281-863-3213,
Press spacebar to pause and continue. Press esc to stop.